Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Early Phase 1
2(50.0%)
4Total
Phase 2(2)
Early Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06220214Early Phase 1Recruiting

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

Role: lead

NCT04542135Phase 2Completed

Sulindac and Breast Density in Women at Risk of Developing Breast Cancer

Role: lead

NCT02613416Phase 2Completed

Denosumab and MRI Breast Imaging

Role: lead

NCT04088032Early Phase 1Withdrawn

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Role: lead

All 4 trials loaded